Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 58.55
+0.76 (1.32%)
At close: Aug 27, 2026
SHA:688192 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 968.83 | 801.14 | 359.9 | 91.29 | - | 10.29 |
| 968.83 | 801.14 | 359.9 | 91.29 | - | 10.29 | |
Revenue Growth | 89.46% | 122.60% | 294.25% | - | - | -62.95% |
Cost of Revenue | 39.49 | 34.23 | 9.32 | 7.66 | 3.65 | 12.93 |
Gross Profit | 929.33 | 766.91 | 350.58 | 83.63 | -3.65 | -2.65 |
Selling, General & Admin | 711.69 | 730.95 | 598.78 | 437.55 | 128.44 | 87.95 |
Research & Development | 849.37 | 855.61 | 723.69 | 801.15 | 660.87 | 583.67 |
Other Operating Expenses | 23.95 | -0.85 | 0.67 | -0.27 | -0.39 | 0.1 |
Operating Expenses | 1,586 | 1,587 | 1,323 | 1,239 | 788.9 | 671.73 |
Operating Income | -656.86 | -819.97 | -972.43 | -1,155 | -792.55 | -674.37 |
Interest Expense | -33.6 | -33.6 | -25.81 | -7.57 | -4.34 | -3.07 |
Interest & Investment Income | 2.14 | 2.14 | 2.24 | 3.64 | 2.53 | 3.65 |
Currency Exchange Gain (Loss) | -1.01 | -1.01 | -2.45 | -1.45 | 10.1 | -6.45 |
Other Non Operating Income (Expenses) | 3.16 | 2.28 | 2.99 | -0.04 | -0.03 | -0.08 |
EBT Excluding Unusual Items | -686.17 | -850.16 | -995.46 | -1,161 | -784.3 | -680.32 |
Gain (Loss) on Sale of Investments | 27.78 | 25.33 | 14.45 | 22.52 | 42.16 | 0.97 |
Gain (Loss) on Sale of Assets | 0.08 | 0 | - | -0.01 | 0.02 | - |
Other Unusual Items | 57.71 | 57.71 | 41.36 | 30.5 | 6.39 | 9.47 |
Pretax Income | -600.6 | -767.13 | -939.65 | -1,108 | -735.74 | -669.88 |
Income Tax Expense | 1.97 | 1.39 | 0 | 0.1 | 0.26 | - |
Earnings From Continuing Operations | -602.57 | -768.52 | -939.66 | -1,108 | -736 | -669.88 |
Minority Interest in Earnings | 5.51 | 4.47 | 93.7 | - | - | - |
Net Income | -597.06 | -764.05 | -845.96 | -1,108 | -736 | -669.88 |
Net Income to Common | -597.06 | -764.05 | -845.96 | -1,108 | -736 | -669.88 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 464 | 447 | 415 | 407 | 404 | 360 |
Shares Outstanding (Diluted) | 464 | 447 | 415 | 407 | 404 | 360 |
Shares Change | 9.39% | 7.75% | 1.83% | 0.70% | 12.29% | 0.07% |
EPS (Basic) | -1.29 | -1.71 | -2.04 | -2.72 | -1.82 | -1.86 |
EPS (Diluted) | -1.29 | -1.71 | -2.04 | -2.72 | -1.82 | -1.86 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -702.9 | -758.79 | -788.1 | -1,000 | -677.15 | -501.26 |
Free Cash Flow Per Share | -1.52 | -1.70 | -1.90 | -2.46 | -1.67 | -1.39 |
Gross Margin | 95.92% | 95.73% | 97.41% | 91.61% | - | -25.72% |
Operating Margin | -67.80% | -102.35% | -270.19% | -1265.43% | - | -6556.55% |
Profit Margin | -61.63% | -95.37% | -235.05% | -1213.42% | - | -6512.85% |
Free Cash Flow Margin | -72.55% | -94.72% | -218.98% | -1095.44% | - | -4873.51% |
EBITDA | -601.75 | -776.5 | -930.7 | -1,114 | -753.85 | -636.97 |
EBITDA Margin | -62.11% | -96.92% | -258.60% | - | - | - |
D&A For EBITDA | 55.11 | 43.47 | 41.73 | 40.94 | 38.7 | 37.4 |
EBIT | -656.86 | -819.97 | -972.43 | -1,155 | -792.55 | -674.37 |
EBIT Margin | -67.80% | -102.35% | -270.19% | - | - | - |
Revenue as Reported | 801.14 | 801.14 | 359.9 | 91.29 | - | 10.29 |
Advertising Expenses | - | 210.92 | 156.99 | - | 1.94 | - |